Anika Therapeutics Inc.
Anika Therapeutics develops and commercializes products based on hyaluronic acid technology. They offer OA pain management products like Monovisc, Orthovisc, and Cingal for osteoarthritis relief. The company also has a joint preservation and restoration product family including Hyalofast, Tactoset, and others. Additionally, they have non-orthopedic products such as veterinary, anti-adhesion barrier, burn treatment, and ophthalmic products. Founded in 1983, the company is headquartered in Bedford, Massachusetts.
Overview
Strengths
- Shareholder-friendly capital allocation: the share count has shrunk by 1.7% a year over the last three years through buybacks.
Weaknesses
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 3 of the last 7 years.
- High leverage: net debt is 5.9x EBITDA, against a median of 1.4x for its Drug Manufacturers - Specialty & Generic peers.
- Our discounted cash flow target price (0.59 USD) is 96% below the current price.
- Unstable profitability: operating margin ranged from -13% to 30% over the last 7 years, with operating losses in 4 of them.
- Margin pressure: gross margin fell 6.8 percentage points last year, pointing to pricing pressure or rising costs.
Key Financial Data